Pharmacovigilance July – September 2022/2023 Q1
- File Size 0.00 KB
- File Count 0
- Create Date March 9, 2023
- Last Updated March 20, 2023
Pharmacovigilance July - September 2022/2023 Q1
The Pharmacy and Poisons Board is the Drug Regulatory Authority established under the Pharmacy and Poisons Act, Chapter 244 of the Laws of Kenya. The Board regulates the Practice of Pharmacy and the manufacture and trade of drugs and poisons.
PPB has 4 directorates and one of them is the directorate of Health Products and Technologies (HPT). Pharmacovigilance & Post Marketing Surveillance are divisions in the department of product safety that falls under HPT. Other divisions Clinical Trials & Medicines Information. Product safety shares quarterly pharmacovigilance reports with stakeholders to serve as a feedback mechanism and also encourage all stakeholders to report.
In this quarter 1 period, a total of 573 adverse events reports were submitted to PPB. 316 of the total reports were of suspected adverse drug reactions (sADRs), 58 adverse events following immunizations (AEFI), 70 from members of the public (PADRs) and 129 were medication error reports. The was no report submitted on blood transfusion reactions.
Since the introduction of PV in Kenya, a total of 16,051 individual case safety reports has been submitted to the global data reports 32,760,345 (0.05%).